Skip to main content

Table 1 Baseline characteristics of the study population, by group

From: Impact on antimicrobial consumption of procalcitonin-guided antibiotic therapy for pneumonia/pneumonitis associated with aspiration in comatose mechanically ventilated patients: a multicenter, randomized controlled study

  PCT group (n = 81) Control group (n = 78) P
Age (years) 53.8 ± 17.8 52.0 ± 17.2 0.54
Male sex 53 (65) 41 (53) 0.1
Origin before ICU admission    0.68
 Home 69 (86) 69 (89)  
 Medical ward 11 (14) 9 (12)  
Comorbidities
 Smoking 35 (43) 32 (41) 0.78
 Chronic alcohol consumption 28 (35) 20 (26) 0.22
 COPD/asthma 3 (4) 3 (4) 1
 Chronic heart failure 5 (6) 2 (3) 0.44
 Chronic renal failure 2 (3) 2 (3) 1
 Chronic respiratory failure 1 (1) 0 1
SOFA Score 6.2 ± 1.9 6.1 ± 1.9 0.76
SAPS II Score 48.9 ± 10.9 45.2 ± 9.5 0.02
Glasgow Score before intubation 4 [3, 6] 5 [3, 6] 0.47
PaO2/FiO2 ratio at inclusion 308.4 ± 105.6 317.0 ± 94.8 0.59
Coma etiology
 Toxic 39 (48) 41 (53) 0.57
 Epilepsy 36 (44) 29 (37) 0.35
 Stroke 17 (10) 11 (6) 0.25
 Metabolic disorders 4 (5) 1 (1) 0.37
 Cerebral tumor 1 (1) 4 (4) 0.2
 Hemodynamic 0 5 (6) 0.03
 Other 3 (4) 4 (8) 0.72
  1. PCT procalcitonin, COPD chronic obstructive pulmonary disease, SOFA Sequential Organ Failure Assessment, SAPS II Simplified Acute Physiological Score II, IQR interquartile range